Biotie Therapies

Biotie Therapies advances value drivers in CNS and inflammation

Thomas Kronbach Ph.D.
Chief Scientific Officer

About Biotie

Biotie develops “first in class” CNS projects. Nalmefene is in phase 3 with partner Lundbeck. It changes the current treatment paradigm against alcohol addiction. Data from the clinical program is expected around year-end 2010 and filing in Europe is expected in the second half of 2011. In a research collaboration with Pfizer we are producing clinical candidate PDE10 inhibitors as a novel approach to treat Schizophrenia. Pfizer has licensed the world-wide rights for these compounds. These programs - together with our monoclonal anti-VAP-1 antibody (Phase 1B for rheumatoid arthritis and psoriasis, partnered with Roche) and ELB353 (Phase 1), an anti-inflammatory PDE4 inhibitor - provide for an interesting news flow during 2010.

About the speaker
Thomas Kronbach (1952) has been appointed as member of the Management Team of Biotie therapies in November 2008 as Chief Scientific Officer. Prior to this, he was Chief Scientific Officer of elbion and its co-founder. Before joining elbion, he was the head of research and development of AWD, a company of the Degussa group. Previously, he had worked with Goedecke-Parke-Davis in Freiburg, Germany, The Scripps Research Institute, La Jolla, California, USA, and the Biocenter of the University of Basle, Switzerland. His key expertise areas are chemistry, pharmacology, molecular biology and drug metabolism. He holds a Ph.D in chemistry from the University of Tuebingen, Germany.

Return to the program overview